Tag: ASH22

lymphoma
January 27, 2023/Cancer/Research

Pembrolizumab Following Autologous Stem Cell Transplantation Shows Promise in T-Cell Non-Hodgkin’s Lymphoma

62% of patients were progression-free at 18 months post-transplantation

22-CNR-3405922-CQD-Hero-650×450 (1)
January 24, 2023/Cancer/Research

Graft Failure Rates Negligible Between Patients with Haplo-Identical Donors and those with Matched Unrelated Donors Receiving Cyclophosphamide

Study assesses the impact of donor source and post-transplant prophylaxis for patients receiving a hematopoietic cell transplant

breast cancer cells
December 16, 2022/Cancer/Research

Researchers Identify Risk Factors of Secondary Malignancy in Breast Cancer Survivors

Prior history of autoimmunity and solid organ transplantation significantly increases chance of myelodysplastic syndrome or acute myeloid leukemia

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Dr. Caimi
December 13, 2022/Cancer/Research

Study Provides Insights about Chemorefractory Diffuse Large B-Cell Lymphoma

Patients who relapse early after first-line chemotherapy are often, but not always, refractory to second-line chemotherapy

22-CNR-3405917-CQD-Hero-650×450 blood clot
December 12, 2022/Cancer/Research

Study Finds Biomarkers of Complications in Patients with Cancer Diagnosed with COVID-19

Elevated levels of vWF and FVIII associated with risk of blood clots, severe COVID-19 and death

22-CNR-3344410-CQD-Hero-650×450 Dr Gerds Momentum trial
December 9, 2022/Cancer/Research

Sustained Response Observed in MOMENTUM Trial of Patients with Myelofibrosis

Study matches momelotinib against danazol

BackPage 1 of 1Next
Advertisement
Ad